Raymond James analyst Martin Auster downgraded BridgeBio Pharma (NASDAQ: BBIO) from Outperform to Market Perform.The analyst comments: “Attruby continues to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE